CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 6 No. 4
 

Myoepithelial Cells May Be Key to Suppression of DCIS Growth

April 1, 1997

LOS ANGELES--Laboratory studies from the UCLA School of Medicine point to a role for myoepithelial cells in suppressing breast cancer invasion, said researcher Mark Sternlicht, PhD. Myo-epithelial cells lie between the epithelium and the basement membrane. They synthesize and maintain the basement membrane and can promote epithelial differentiation. They are found surrounding benign and nonmalignant lesions.

"Myoepithelial cells rarely transform," Dr. Sternlicht said at the San Antonio Breast Cancer Symposium. "And when they do, they transform to benignity or low-grade neoplasms that do not invade and do not metastasize."

Surrogates Developed

Researchers at the UCLA laboratory, under the direction of Dr. Sanford Barsky, have developed cell lines and transplantable xenografts from benign myoepithe-lial tumors to serve as a surrogate to study the effects of myoepithelial cells on breast cancer invasion.

"These myoepithelial tumors are slow growing; it takes six months of nude mouse growth to reach about 1.5 cm in diameter," Dr. Sternlicht said. He noted that these tumors make an abundant extracellular matrix, composed of a number of basement membrane and non-basement membrane molecules.

More importantly, he said, myoepithe-lial cells express high levels of proteinase inhibitors and angiogenic inhibitors, and very low levels of proteinase and no angiogenic-stimulating factors. Many of these proteinase and angiogenic inhibitors can be seen selectively in tissue sections of ductal carcinoma in situ (DCIS) in the surrounding myoepithelial layer.

One of the myoepithelial cell lines, HMS1, has been shown in vitro to dramatically inhibit tumor invasion and angiogenesis (endothelial cell migration and mitogenesis). The UCLA work further suggests that the anti-invasive effect is mediated in part through maspin, a member of the serpin superfamily of proteinase inhibitors, while the angiogenic inhibition is mediated primarily through thrombospondin-1.

With all of this evidence for the "myoepithelial defense," Dr. Sternlicht hypothesizes that DCIS is regulated by the paracrine interaction of the myoepi-thelial cells and "this is why DCIS stays confined for so many years and why there is no demonstrable genetic alteration between DCIS and invasive cancer."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy